AMAG Pharma Q3 top-line down 31%

AMAG Pharmaceuticals (AMAG) Q3 results: Revenues: $84.1M (-31.2%); Feraheme: $44.2M (+19.5%); Makena: $34.3M (-57.2%); Intrarosa: $5.6M (+12.0%).

Net loss: ($23.6M) (+63.5%); loss/share: ($0.70) (+62.8%); CF Ops: ($105.7M) (-224.5%).

Non-GAAP EBITDA: ($8.2M) (-127.3%).

2019 guidance: Revenue: $320M – 330M from $325M – 355M; non-GAAP EBITDA: ($75M – 65M) from ($85M – 75M).

The company launched Vyleesi (bremelanotide injection) nationally in September.

Previously: AMAG Pharmaceuticals EPS beats by $0.09, misses on revenue (Nov. 1)

https://seekingalpha.com/news/3512959-amag-pharma-q3-top-line-31-percent